AA
TRVI icon

ALPS Advisors’s Trevi Therapeutics TRVI Stock Holding History

ALPS Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-58,292
Closed -$533K – 1084
2025
Q3 		$533K Sell
58,292
-6,002
-9% -$45K ﹤0.01% 655
2025
Q2 		$352K Buy
+64,294
New +$400K ﹤0.01% 867

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

ALPS Advisors's TRVI Position: Q4 2025 in Review

ALPS Advisors sold out of Trevi Therapeutics (TRVI) in Q4 2025, closing a stake of 58,292 shares — an estimated $533K sold.

ALPS Advisors first reported a position in TRVI in Q2 2025 and held it in 2 quarters. The position peaked at $533K in Q3 2025. 184 funds tracked by Wall St. Rank hold TRVI as of Q4 2025.

  • ALPS Advisors reported no remaining Trevi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 58,292 Trevi Therapeutics shares in Q4 2025, an estimated $533K.
  • ALPS Advisors first reported a position in Trevi Therapeutics in Q2 2025 and held it in 2 quarters.
  • ALPS Advisors's Trevi Therapeutics position peaked at $533K in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.